oncbrain — oncology meeting digest

FIRESTORM

Tue, 09 Jun 2026 00:00:00 GMT

[Caveats dominate] 5-yr PFS 65.8% vs 38.8%, HR 0.40 favoring dose-escalated RT in high-risk meningioma; retrospective IPD meta-analysis. Eligible: High-risk meningioma (WHO grade 2 or recurrent), post-resection (mostly subtotal

DeLLphi-304 (tarlatamab CNS outcomes)

Mon, 01 Jun 2026 00:00:00 GMT

[Caveats dominate] CNS PFS HR 0.54 (ITT), HR 0.40 in brain mets; CNS CR 14.9% vs 5.4% with tarlatamab vs chemo 2L SCLC. Eligible: 2L ES-SCLC; brain mets subgroup ≥1 BM at baseline, >70% prior CNS treatment

PROTEUS

Sun, 31 May 2026 00:00:00 GMT

[Caveats dominate] 53.0% (APA) and 60.7% (ADT) of MFS events PSMA PET-detected; APA+ADT vs ADT benefit in BCR prostate hotly contested. Eligible: Biochemically recurrent prostate cancer, post-radical prostatectomy

COMPPARE

Sun, 31 May 2026 00:00:00 GMT

[Caveats dominate] No sig difference (bowel urgency 5.7% vs 6%, p=0.28; 3-yr BCF 98.0% vs 97.9%) between proton and IMRT in de novo localized prostate. Eligible: De novo localized prostate cancer, excluding very high risk and metastatic

ENZAMET + Decipher Biomarker Analysis

Sat, 30 May 2026 00:00:00 GMT

[Caveats dominate] Decipher >0.85 identifies mHSPC pts with OS benefit from docetaxel intensification; IPTW interaction p=0.04, HR 0.75 (0.43-1.33). Eligible: mHSPC, ADT + enzalutamide backbone, tumor tissue available for Decipher testing

SPIN Score (Celiac Plexus SRS)

Sat, 30 May 2026 00:00:00 GMT

[Caveats dominate] 89% pain response in SPIN-2 pts (baseline pain >6 + no prior neurotoxic chemo) vs 32% SPIN-0 after celiac SRS. Eligible: Pancreatic cancer, intractable retroperitoneal pain, planned celiac plexus SRS

SWOG S1007 RNI analysis

Thu, 21 May 2026 00:00:00 GMT

[Caveats dominate] 5-yr LRR <1% with or without RNI in HR+/HER2-, Oncotype ≤25, N1 breast; IDFS not associated with RNI receipt. Eligible: HR+/HER2-, Oncotype DX ≤25, N1 (1-3 nodes) breast cancer, adjuvant

Proton vs Photon PMRT Capsular Contracture (Zerey et al.)

Wed, 20 May 2026 00:00:00 GMT

[Caveats dominate] MVA HR 1.76 (P=0.083) proton vs photon CC, non-significant; proton+DTI 2yr CC 50% vs photon+DTI 35%. Eligible: Post-mastectomy breast cancer, subpectoral TE/I or DTI reconstruction, PMRT cand

OPERA Trial (5-year, rectal preservation)

Mon, 18 May 2026 00:00:00 GMT

[Caveats dominate] 76% good response at W14 by clinical exam; 5yr OP 81% cCR vs 77% nCR; W14 assessment safely identifies W&W candidates. Eligible: Locally advanced rectal cancer, post-neoadjuvant therapy

RADIOSA

Sun, 17 May 2026 00:00:00 GMT

[Caveats dominate] Post-hoc: SBRT + 6mo ADT vs SBRT alone in oligorecurrent prostate; median MFS 16.6mo vs NR, HR 0.39, p=0.0012. Eligible: Oligorecurrent prostate cancer, SBRT candidates, median f/u ~4yr